The mIF assay is of particular interest in breast cancer because it may serve to complement two clinically developed I-O biomarkers, PD-L1 expression (by the Ventana SP142 assay), and the hematoxylin and eosin (H&E) stromal tumor-infiltrating lymphocyte (sTIL) score. The gene discussed is CD274; the disease is breast cancer.